| 0.6755 -0.019 (-2.75%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.08  |
1-year : | 1.28 |
| Resists | First : | 0.92 |
Second : | 1.1 |
| Pivot price | 0.83 |
|||
| Supports | First : | 0.65 |
Second : | 0.54 |
| MAs | MA(5) : | 0.71 |
MA(20) : | 0.87 |
| MA(100) : | 0.94 |
MA(250) : | 3.77 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.3  |
D(3) : | 5 |
| RSI | RSI(14): 29.4 |
|||
| 52-week | High : | 11.9 | Low : | 0.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALZN ] has closed above bottom band by 3.0%. Bollinger Bands are 12.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.71 - 0.72 | 0.72 - 0.72 |
| Low: | 0.64 - 0.65 | 0.65 - 0.65 |
| Close: | 0.67 - 0.68 | 0.68 - 0.68 |
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Tue, 02 Apr 2024
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying - Alzamend Neuro (NASDAQ:ALZN), Anitra (AMEX: - Benzinga
Thu, 28 Mar 2024
Alzamend Neuro director Milton Ault III acquires $936k in company stock - Investing.com
Tue, 26 Mar 2024
Alzamend Neuro Inc Down 2.97% To $0.98 After Earnings Miss - InvestorsObserver
Sat, 03 Feb 2024
Alzamend Neuro Risks Nasdaq Delisting Over Price Deficiency - TipRanks.com - TipRanks
Sat, 03 Feb 2024
Alzamend Neuro Secures Funding Through Preferred Stock Sale - TipRanks.com - TipRanks
Wed, 10 Jan 2024
Alzamend Neuro And 3 Other Stocks Under $3 Insiders Are Buying - Alzamend Neuro (NASDAQ:ALZN), Fortress B - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 4.83e+006 (%) |
| Held by Institutions | 29.6 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.235e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -166.9 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9813 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.03 |
| Dividend | 0 |
| Forward Dividend | 45310 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|